[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2099796T3 - Związki azaindolilowe i sposoby ich zastosowania - Google Patents

Związki azaindolilowe i sposoby ich zastosowania

Info

Publication number
PL2099796T3
PL2099796T3 PL07854844T PL07854844T PL2099796T3 PL 2099796 T3 PL2099796 T3 PL 2099796T3 PL 07854844 T PL07854844 T PL 07854844T PL 07854844 T PL07854844 T PL 07854844T PL 2099796 T3 PL2099796 T3 PL 2099796T3
Authority
PL
Poland
Prior art keywords
aza
methods
indolyl compounds
indolyl
compounds
Prior art date
Application number
PL07854844T
Other languages
English (en)
Inventor
Simon Charles Goodacre
Karen Williams
Stephen Price
Hazel Joan Dyke
John Gary Montana
Mark S Stanley
Liang Bao
Wendy Lee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PL2099796T3 publication Critical patent/PL2099796T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07854844T 2006-11-30 2007-11-29 Związki azaindolilowe i sposoby ich zastosowania PL2099796T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US91762007P 2007-05-11 2007-05-11
US94474307P 2007-06-18 2007-06-18
PCT/US2007/085962 WO2008067481A1 (en) 2006-11-30 2007-11-29 Aza-indolyl compounds and methods of use
EP07854844A EP2099796B1 (en) 2006-11-30 2007-11-29 Aza-indolyl compounds and methods of use

Publications (1)

Publication Number Publication Date
PL2099796T3 true PL2099796T3 (pl) 2011-10-31

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07854844T PL2099796T3 (pl) 2006-11-30 2007-11-29 Związki azaindolilowe i sposoby ich zastosowania

Country Status (15)

Country Link
US (1) US7855216B2 (pl)
EP (1) EP2099796B1 (pl)
JP (1) JP5211063B2 (pl)
AR (1) AR064031A1 (pl)
AT (1) ATE511509T1 (pl)
AU (1) AU2007325123B2 (pl)
CA (1) CA2672327A1 (pl)
CL (1) CL2007003444A1 (pl)
DK (1) DK2099796T3 (pl)
HK (1) HK1135099A1 (pl)
PE (1) PE20081354A1 (pl)
PL (1) PL2099796T3 (pl)
PT (1) PT2099796E (pl)
TW (1) TW200829586A (pl)
WO (1) WO2008067481A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110137063A1 (en) * 2008-07-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft Compounds and processes for production of radiopharmaceuticals
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
CN103002894B (zh) 2010-02-25 2016-04-06 达纳－法伯癌症研究所公司 对braf抑制剂具有抗性的braf突变
AU2011224410B2 (en) 2010-03-09 2015-05-28 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
RU2582610C2 (ru) * 2010-07-30 2016-04-27 Онкотерапи Сайенс, Инк. Производные хинолина и содержащие их ингибиторы melk
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
JP2019518426A (ja) 2016-04-15 2019-07-04 ジェネンテック， インコーポレイテッド がんの診断及び治療方法
EP3624795B1 (en) 2017-05-19 2022-04-20 NFlection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
KR102642411B1 (ko) * 2017-05-19 2024-02-28 엔플렉션 테라퓨틱스, 인코포레이티드 피부병 치료를 위한 피롤로피리딘-아닐린 화합물
TW202428305A (zh) 2017-09-08 2024-07-16 美商建南德克公司 癌症之診斷及治療方法
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
AU2019383311A1 (en) 2018-11-20 2021-06-10 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
AU2023213905A1 (en) * 2022-01-28 2024-07-11 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ES2330628T3 (es) 2002-04-23 2009-12-14 Aventis Pharmaceuticals Inc. Ester del acido 3-(amino sustituido)-1h-indol-2-carboxilico y derivados del ester del acido 3-(amino sustituido)-benzo(b)tiofeno-2-carboxilico como imhibidores de expresion del gen de interleucina-4.
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
PE20060526A1 (es) * 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Also Published As

Publication number Publication date
AU2007325123A1 (en) 2008-06-05
PT2099796E (pt) 2011-09-06
AU2007325123B2 (en) 2012-12-13
US20080242655A1 (en) 2008-10-02
CL2007003444A1 (es) 2008-06-27
AR064031A1 (es) 2009-03-04
WO2008067481A1 (en) 2008-06-05
HK1135099A1 (en) 2010-05-28
EP2099796A1 (en) 2009-09-16
DK2099796T3 (da) 2011-09-05
TW200829586A (en) 2008-07-16
ATE511509T1 (de) 2011-06-15
JP5211063B2 (ja) 2013-06-12
EP2099796B1 (en) 2011-06-01
US7855216B2 (en) 2010-12-21
JP2010511626A (ja) 2010-04-15
CA2672327A1 (en) 2008-06-05
PE20081354A1 (es) 2008-11-14

Similar Documents

Publication Publication Date Title
HK1135099A1 (en) Aza-indolyl compounds and methods of use
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL176958A0 (en) Compounds and methods of use
IL186970A0 (en) Thiazole compounds and methods of use
GB0718972D0 (en) Compounds and methods of making the compounds
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
IL189602A0 (en) Indenoisoquinolinone analogs and methods of use thereof
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
EP2021555A4 (en) STRUCTURAL ELEMENT AND METHODS OF USE THEREOF
IL190226A0 (en) Organometallic compounds and methods of use thereof
HK1161122A1 (en) Use of 24-norudca 24-norudca
EP2069371A4 (en) ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
IL192820A0 (en) Novel compounds and use thereof
EP1978999A4 (en) ISOLATED MCPIP PROTEIN AND METHODS OF USE
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
ZA200710971B (en) Elasmobranch-repelling compounds and methods of use
GB0507211D0 (en) Method and uses of compounds
AU2006907075A0 (en) Compounds and Methods of Use
IL198709A0 (en) Nitrogen-containing heterocyclic compounds and methods of use thereof
ZA200903345B (en) Nitrogen-containing heterocyclic compounds and methods of use thereof